Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.75 USD | +0.83% | -1.36% | -3.89% |
04-12 | Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing | MT |
04-04 | Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Aerovate Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Aerovate Therapeutics, Inc.
Wedbush | |
Guggenheim | |
BTIG | |
Jefferies & Co. | |
Cowen | |
Evercore ISI |
EPS Revisions
- Stock Market
- Equities
- AVTE Stock
- Consensus Aerovate Therapeutics, Inc.